Multiple system atrophy: an update and emerging directions of biomarkers and clinical trials
M Liu, Z Wang, H Shang - Journal of Neurology, 2024 - Springer
Multiple system atrophy is a rare, debilitating, adult-onset neurodegenerative disorder that
manifests clinically as a diverse combination of parkinsonism, cerebellar ataxia, and …
manifests clinically as a diverse combination of parkinsonism, cerebellar ataxia, and …
Disease-modifying therapies for multiple system atrophy: where are we in 2022?
V Sidoroff, P Bower, N Stefanova… - Journal of …, 2022 - content.iospress.com
Multiple system atrophy is a rapidly progressive and fatal neurodegenerative disorder. While
numerous preclinical studies suggested efficacy of potentially disease modifying agents …
numerous preclinical studies suggested efficacy of potentially disease modifying agents …
[HTML][HTML] Multiple system atrophy-a clinicopathological update
KA Jellinger - Free Neuropathology, 2020 - ncbi.nlm.nih.gov
Multiple system atrophy (MSA) is a fatal, adult-onset neurodegenerative disorder of
uncertain etiology, clinically characterized by various combinations of Levo-dopa …
uncertain etiology, clinically characterized by various combinations of Levo-dopa …
Pathophysiology of COVID‐19‐Related Extrapyramidal Disorders
F Cavallieri, M Zedde, V Fioravanti, S Grisanti… - The COVID-19 Aftermath …, 2024 - Springer
Abstract Coronavirus disease 2019 (COVID-19) has been associated with a variety of
neurological manifestations (ie, anosmia, ageusia, myalgia, headache) and neurological …
neurological manifestations (ie, anosmia, ageusia, myalgia, headache) and neurological …
Novel disease-modifying treatments for synucleinopathies
Misfolding of alpha-synuclein (aSyn), formation of toxic oligomers, and their prion like
spread are considered key mechanisms of disease pathogenesis in multiple system atrophy …
spread are considered key mechanisms of disease pathogenesis in multiple system atrophy …